Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shanu Modi

Showing results (61-70 of 115) with videos related to

Pageof 12
Sort By:
Nuclear Medicine Communications|October 9, 2013
Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancerVolkan Beylergil, Patrick G Morris, Peter M Smith-Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2011
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumabShanu Modi, Alison Stopeck, Hannah Linden, et al.
Advances in Radiation Oncology|March 17, 2025
Local Therapy for Isolated Central Nervous System Progression Among Patients Receiving Antibody-Drug Conjugate TherapyEmily S Lebow, Jordan Eichholz, Zhigang Zhang, et al.
Breast Cancer Research : BCR|August 3, 2017
A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancerKomal Jhaveri, Rui Wang, Eleonora Teplinsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2010
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancerIan E Krop, Muralidhar Beeram, Shanu Modi, et al.
NPJ Breast Cancer|October 18, 2024
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancerNicholas Mai, Carlos H Dos Anjos, Pedram Razavi, et al.
Clinical Breast Cancer|July 10, 2026
Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 StudyShanu Modi, Rashmi K Murthy, A Jo Chien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2007
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation studyShanu Modi, Alison T Stopeck, Michael S Gordon, et al.
Research Square|May 15, 2024
Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Failure in ER+ Metastatic Breast CancerNicholas Mai, Carlos H Dos Anjos, Pedram Razavi, et al.
Clinical Breast Cancer|April 23, 2018
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast CancerPatrick G Morris, Selene Rota, Karen Cadoo, et al.
Pageof 12

Showing results (61-70 of 115) with videos related to

Sort By:
Pageof 12
Nuclear Medicine Communications|October 9, 2013
Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancerVolkan Beylergil, Patrick G Morris, Peter M Smith-Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2011
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumabShanu Modi, Alison Stopeck, Hannah Linden, et al.
Advances in Radiation Oncology|March 17, 2025
Local Therapy for Isolated Central Nervous System Progression Among Patients Receiving Antibody-Drug Conjugate TherapyEmily S Lebow, Jordan Eichholz, Zhigang Zhang, et al.
Breast Cancer Research : BCR|August 3, 2017
A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancerKomal Jhaveri, Rui Wang, Eleonora Teplinsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2010
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancerIan E Krop, Muralidhar Beeram, Shanu Modi, et al.
NPJ Breast Cancer|October 18, 2024
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancerNicholas Mai, Carlos H Dos Anjos, Pedram Razavi, et al.
Clinical Breast Cancer|July 10, 2026
Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 StudyShanu Modi, Rashmi K Murthy, A Jo Chien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2007
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation studyShanu Modi, Alison T Stopeck, Michael S Gordon, et al.
Research Square|May 15, 2024
Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Failure in ER+ Metastatic Breast CancerNicholas Mai, Carlos H Dos Anjos, Pedram Razavi, et al.
Clinical Breast Cancer|April 23, 2018
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast CancerPatrick G Morris, Selene Rota, Karen Cadoo, et al.
Pageof 12